Acid Stable Prolyl Endopeptidases for Degrading Gluten
Gluten-degrading proteases can be used to degrade gluten and for making gluten-containing food safer for patients suffering from gluten intolerance. The present invention provides recombinant expression vectors encoding the proteases of the invention and methods for using such vectors to produce the encoded proteases. In another aspect, the present invention provides pharmaceutical formulations and unit dose forms suitable for oral administration.
1 . A prolyl endopeptidase from the S9 family of proteases that contains a secretion signal sequence isolated from an acidophilic bacteria.
2 . A protease with at least 70% sequence identity to one of SEQ ID:1-6, in isolated, recombinant or purified form.
3 . The protease of claim 2 , wherein the protease has at least 90% sequence identity to one of SEQ ID:1-6.
4 . The protease of claim 2 , wherein the protease has at least 95% sequence identity to one of SEQ ID:1-6.
5 . The protease of claim 4 , wherein said protease digests gluten fragments that are resistant to normal digestive enzymes.
6 . The protease of claim 5 , wherein said protease are formulated with a pharmaceutically acceptable excipient.
7 . The protease of claim 5 , wherein said protease is admixed with food.
8 . The protease according to claim 4 , wherein said protease is stable to acid conditions.
9 . A formulation comprising the protease of claim 8 , in combination with at least one other gluten cleaving protease and a pharmaceutically acceptable excipient.
10 . The formulation of claim 9 , wherein the gluten cleaving protease has a specificity other than that of the S9 family protease.
11 . The formulation of claim 10 , wherein the second gluten-cleaving protease is a cysteine endoprotease.
12 . The formulation of claim 11 , wherein the cysteine endoprotease is cysteine endoprotease B, isoform 2 from barley (EP-B2) (Genbank accession U19384).
13 . The formulation of claim 11 , wherein the cysteine endoprotease is a homolog, ortholog or variant of cysteine endoprotease B, isoform 2 from barley (EP-B2) (Genbank accession U19384).
14 . The formulation of claim 11 , wherein the cysteine endoprotease is a cysteine endoprotease from barley.
15 . The formulation of claim 11 , wherein the cysteine endoprotease is a cysteine endoprotease from a germinating grain.
16 . The formulation of claim 11 , wherein the cysteine endoprotease is an insect enzyme.
17 . The formulation of claim 9 , and further comprising aspergillopepsin I from Aspergillus niger (Genbank ID #EHA27889).
18 . The formulation of claim 9 , wherein the second gluten-cleaving protease is one or more of Hordeum vulgare endoprotease B (Genbank accession U19384); Hordeum vulgare endoprotease A (Genbank accession CAB09697.1); X-Pro dipeptidase from Aspergillus oryzae (GenBank ID #BD191984);
carboxypeptidase from Aspergillus saitoi (GenBank ID #D25288) and aspergillopepsin from Aspergillus niger (GenBank ID #EHA27889).
19 . A recombinant expression vector comprising a coding sequence for a protease, wherein said protease has at least 70% sequence identity to one of SEQ ID:1-6 and a promoter that drives expression of said protease in a suitable host cell.
20 . (canceled)
21 . A method for treating gluten intolerance, celiac disease, dermatitis herpetiformis and/or gluten sensitivity in a patient in need of such treatment, wherein said treatment reduces exposure of said patient to immunogenic gluten peptides, said method comprising the step of orally administering to said patient a therapeutically effective dose of a protease of claim 1 contemporaneously with the ingestion of a food that may contain gluten.
22 . (canceled)